2-氯-3,4-二甲氧基苯甲酰胺 | 175136-02-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-3,4-二甲氧基苯甲酰胺
• 英文名称: 2-Chloro-3,4-dimethoxybenzamide
• CAS: 175136-02-4
• 化学式: C₉H₁₀ClNO₃
• mdl: MFCD00084943
• 分子量: 215.636
• InChiKey: RTGUEWMXSKEOOA-UHFFFAOYSA-N

物化性质

• 熔点：
  165 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-氯-3,4-二甲氧基苯甲酰胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-氯-3,4-二甲氧基苄胺盐酸盐
  参考文献：
  名称：

  Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF

  摘要：

  Catechol-based inhibitors of ERCC1-XPF endonuclease activity were identified from a high-throughput screen. Exploration of the structure-activity relationships within this series yielded compound 13, which displayed an ERCC1-XPF IC50 of 0.6 mu M, high selectivity against FEN-1 and DNase I and activity in nucleotide excision repair, cisplatin enhancement and gamma H2AX assays in A375 melanoma cells. Screening of fragments as potential alternatives to the catechol group revealed that 3-hydroxypyridones are able to inhibit ERCC1-XPF with high ligand efficiency, and elaboration of the hit gave compounds 36 and 37 which showed promising ERCC1-XPF IC50 values of <10 mu M. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.08.031

文献信息

• Novel Microtubule-Interacting Phenoxy Pyridine and Phenyl Sulfanyl Pyridine Analogues for Cancer Therapy
  作者：Ravi Kumar Anchoori、Madeleine Susanne Quirine Kortenhorst、Manuel Hidalgo、Taradas Sarkar、Gurulingappa Hallur、Ruoli Bai、Paul J. Van Diest、Ernest Hamel、Saeed R. Khan

  DOI：10.1021/jm800203e

  日期：2008.10.9

  Current microtubule inhibitory agents used in the clinic to treat cancer have severe side effects, and development of resistance is frequent. We have evaluated the antitumor effect of a novel 30-compound library of phenoxy pyridine and phenyl sulfanyl pyridine derivatives. MTT assays revealed that, of all 30 compounds tested, compounds 2 and 3 showed the largest decrease in proliferation (low mu M range) against Panel and HS766T human pancreatic cancer cells. Flow cytometry experiments with MCF7 breast cancer cells showed a G2/M arrest comparable to that of colcemid. Immunofluorescence staining demonstrated complete disappearance of intracellular microtubules. Tubulin assembly assays, however, showed a dose-dependent decrease in tubulin assembly with compound 3 that seemed limited to about 50% of the control reaction. With compound 2 treatment, there was only a delay in the onset of assembly, with no effect on the extent of the reaction. Taken together, our results show that these novel microtubule inhibitors have promising anticancer activity and can be potentially used to overcome paclitaxel resistance in the clinical setting.
• Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF
  作者：Timothy M. Chapman、Kevin J. Gillen、Claire Wallace、Maximillian T. Lee、Preeti Bakrania、Puneet Khurana、Peter J. Coombs、Laura Stennett、Simon Fox、Emilie A. Bureau、Janet Brownlees、David W. Melton、Barbara Saxty

  DOI：10.1016/j.bmcl.2015.08.031

  日期：2015.10

  Catechol-based inhibitors of ERCC1-XPF endonuclease activity were identified from a high-throughput screen. Exploration of the structure-activity relationships within this series yielded compound 13, which displayed an ERCC1-XPF IC50 of 0.6 mu M, high selectivity against FEN-1 and DNase I and activity in nucleotide excision repair, cisplatin enhancement and gamma H2AX assays in A375 melanoma cells. Screening of fragments as potential alternatives to the catechol group revealed that 3-hydroxypyridones are able to inhibit ERCC1-XPF with high ligand efficiency, and elaboration of the hit gave compounds 36 and 37 which showed promising ERCC1-XPF IC50 values of <10 mu M. (C) 2015 Elsevier Ltd. All rights reserved.